In Vivo and In Vitro Models of Hepatic Fibrosis for Pharmacodynamic Evaluation and Pathology Exploration

被引:0
|
作者
Hu, Yanting [1 ]
Zhang, Zhongrui [1 ]
Adiham, Akida [1 ]
Li, Hong [1 ]
Gu, Jian [1 ]
Gong, Puyang [1 ]
机构
[1] Southwest Minzu Univ, Coll Pharm & Food, Chengdu 610093, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatic fibrosis; hepatic stellate cells; animal model; drug screening; LIVER FIBROSIS; STELLATE CELLS; BILIARY ATRESIA; STEM-CELLS; TGF-BETA; MECHANISMS; HEPATOCYTE; EXPANSION; INJURY; MOUSE;
D O I
10.3390/ijms26020696
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatic fibrosis (HF) is an important pathological state in the progression of chronic liver disease to end-stage liver disease and is usually triggered by alcohol, nonalcoholic fatty liver, chronic hepatitis viruses, autoimmune hepatitis (AIH), or cholestatic liver disease. Research on novel therapies has become a hot topic due to the reversibility of HF. Research into the molecular mechanisms of the pathology of HF and potential drug screening relies on reliable and rational biological models, mainly including animals and cells. Hence, a number of modeling approaches have been attempted based on human dietary, pathological, and physiological factors in the development of HF. In this review, classical and novel methods of modeling HF in the last 10 years were collected from electronic databases, including Web of Science, PubMed, ScienceDirect, ResearchGate, Baidu Scholar, and CNKI. Animal models of HF are usually induced by chemical toxicants, special diets, pathogenic microorganisms, surgical operations, and gene editing. The advantages and limitations of hepatic stellate cells (HSCs), organoids, and 3D coculture-based HF modeling methods established in vitro were also proposed and summarized. This information provides a scientific basis for the discovery of the pathological mechanism and treatment of HF.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] In vitro models of infection: Pharmacokinetic/pharmacodynamic correlates
    MacGowan, AP
    FIRST INTERNATIONAL MOXIFLOXACIN SYMPOSIUM - BERLIN, 1999, 2000, : 104 - 110
  • [42] Evaluation of several in vitro and in vivo models for oxidative stress.
    Lesage, AS
    VanAssouw, H
    VanGompel, P
    Cik, M
    Leysen, J
    JOURNAL OF NEUROCHEMISTRY, 1996, 66 : S33 - S33
  • [43] Evaluation of several in vitro models:: Approximation of midazolam concentrations in vivo
    Ucpinar, SD
    Fisher, CW
    Black, CB
    DRUG METABOLISM REVIEWS, 2002, 34 : 76 - 76
  • [44] Protocols for the Evaluation of Neurodevelopmental Alterations in Rabbit Models In Vitro and In Vivo
    Pla, Laura
    Kuhne, Britta Anna
    Guardia-Escote, Laia
    Vazquez-Aristizabal, Paula
    Loreiro, Carla
    Flick, Burkhard
    Gratacos, Eduard
    Barenys, Marta
    Illa, Miriam
    FRONTIERS IN TOXICOLOGY, 2022, 4
  • [45] Microencapsulation of hydroxyzine HCl by thermal phase separation: in vitro release enhancement and in vivo pharmacodynamic evaluation
    Rizkalla, Christianne Mounir Zaki
    Aziz, Randa Latif
    Soliman, Iman Ibrahim
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2013, 18 (01) : 196 - 209
  • [46] Synthesis and pharmacodynamic evaluation of 2-aminoindole derivatives against influenza A virus in vitro/vivo
    Zhang, Zhongmou
    Wang, Nanfang
    Lu, Jiejie
    Qu, Ying
    Song, Yihui
    Yang, Xinyu
    Wei, Zhanyong
    Zhang, Qi
    Herdewijn, Piet
    Chang, Junbiao
    Wang, Xiao-Na
    Wang, Zhenya
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 281
  • [47] Screening and pharmacodynamic evaluation of the antirespiratory syncytial virus activity of steroidal pyridine compounds in vitro and in vivo
    Wang, Zhenya
    Hou, Duoduo
    Fang, Jieyu
    Zhu, Li
    Sun, Yingying
    Tan, Yayun
    Gu, Zichen
    Shan, Lihong
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (06) : 3428 - 3438
  • [48] Pharmacodynamic effects of ciprofloxacin, fleroxacin and lomefloxacin in vivo and in vitro
    Fuentes, F
    Martin, MM
    Izquierdo, J
    GomezLus, ML
    Prieto, J
    CHEMOTHERAPY, 1996, 42 (05) : 354 - 362
  • [49] Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo
    Li, Qinghua
    Ding, Youcheng
    Guo, Xinlai
    Luo, Shenggen
    Zhuang, Huiren
    Zhou, JingE
    Xu, Nan
    Yan, Zhiqiang
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (03) : 1951 - 1962
  • [50] Raf Kinase Inhibitory Protein Down-Expression Exacerbates Hepatic Fibrosis In Vivo and In Vitro
    Huang, Quanfang
    Liang, Chunhong
    Wei, Ling
    Nie, Jinlan
    Lu, Shengjuan
    Lu, Chunyuan
    Zhuo, Lang
    Lu, Zhongpeng
    Lin, Xing
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 40 (1-2) : 49 - 61